Logo image of IMUX

IMMUNIC INC (IMUX) Stock Fundamental Analysis

NASDAQ:IMUX - Nasdaq - US4525EP1011 - Common Stock - Currency: USD

0.9891  +0.01 (+0.93%)

After market: 1.01 +0.02 (+2.11%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IMUX. IMUX was compared to 568 industry peers in the Biotechnology industry. While IMUX seems to be doing ok healthwise, there are quite some concerns on its profitability. IMUX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMUX had negative earnings in the past year.
IMUX had a negative operating cash flow in the past year.
In the past 5 years IMUX always reported negative net income.
In the past 5 years IMUX always reported negative operating cash flow.
IMUX Yearly Net Income VS EBIT VS OCF VS FCFIMUX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -245.93%, IMUX is doing worse than 91.90% of the companies in the same industry.
IMUX's Return On Equity of -545.37% is on the low side compared to the rest of the industry. IMUX is outperformed by 80.28% of its industry peers.
Industry RankSector Rank
ROA -245.93%
ROE -545.37%
ROIC N/A
ROA(3y)-170.85%
ROA(5y)-121.12%
ROE(3y)-324.95%
ROE(5y)-215.14%
ROIC(3y)N/A
ROIC(5y)N/A
IMUX Yearly ROA, ROE, ROICIMUX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMUX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMUX Yearly Profit, Operating, Gross MarginsIMUX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, IMUX has more shares outstanding
The number of shares outstanding for IMUX has been increased compared to 5 years ago.
IMUX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMUX Yearly Shares OutstandingIMUX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IMUX Yearly Total Debt VS Total AssetsIMUX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -22.40, we must say that IMUX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IMUX (-22.40) is worse than 87.15% of its industry peers.
IMUX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.4
ROIC/WACCN/A
WACCN/A
IMUX Yearly LT Debt VS Equity VS FCFIMUX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

IMUX has a Current Ratio of 1.77. This is a normal value and indicates that IMUX is financially healthy and should not expect problems in meeting its short term obligations.
IMUX has a Current ratio of 1.77. This is in the lower half of the industry: IMUX underperforms 78.17% of its industry peers.
A Quick Ratio of 1.77 indicates that IMUX should not have too much problems paying its short term obligations.
The Quick ratio of IMUX (1.77) is worse than 76.94% of its industry peers.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.77
IMUX Yearly Current Assets VS Current LiabilitesIMUX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

IMUX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.61%, which is quite impressive.
EPS 1Y (TTM)52.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 46.85% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.4%
EPS Next 2Y16.4%
EPS Next 3Y12.54%
EPS Next 5Y46.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMUX Yearly Revenue VS EstimatesIMUX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 1B 2B 3B 4B
IMUX Yearly EPS VS EstimatesIMUX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600 -800 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMUX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMUX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMUX Price Earnings VS Forward Price EarningsIMUX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMUX Per share dataIMUX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as IMUX's earnings are expected to grow with 12.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.4%
EPS Next 3Y12.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMUX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNIC INC

NASDAQ:IMUX (4/21/2025, 8:22:32 PM)

After market: 1.01 +0.02 (+2.11%)

0.9891

+0.01 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/bmo
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners59.43%
Inst Owner Change0.01%
Ins Owners1.01%
Ins Owner Change2.15%
Market Cap94.78M
Analysts84.62
Price Target14.45 (1360.92%)
Short Float %2.69%
Short Ratio2.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.8%
Min EPS beat(2)-8.03%
Max EPS beat(2)-3.56%
EPS beat(4)1
Avg EPS beat(4)-3.24%
Min EPS beat(4)-13.12%
Max EPS beat(4)11.76%
EPS beat(8)3
Avg EPS beat(8)-0.83%
EPS beat(12)5
Avg EPS beat(12)-9.57%
EPS beat(16)7
Avg EPS beat(16)-16.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.59%
PT rev (3m)10.8%
EPS NQ rev (1m)3.01%
EPS NQ rev (3m)-5.67%
EPS NY rev (1m)1.4%
EPS NY rev (3m)1.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.14
P/tB 5.14
EV/EBITDA N/A
EPS(TTM)-1
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -245.93%
ROE -545.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.85%
ROA(5y)-121.12%
ROE(3y)-324.95%
ROE(5y)-215.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 197.02%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.77
Altman-Z -22.4
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)211.81%
Cap/Depr(5y)217.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.92%
EPS Next Y28.4%
EPS Next 2Y16.4%
EPS Next 3Y12.54%
EPS Next 5Y46.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.68%
OCF growth 3YN/A
OCF growth 5YN/A